Remikiren
- Product Name
- Remikiren
- CAS No.
- 126222-34-2
- Chemical Name
- Remikiren
- Synonyms
- D09038;C07465;AC1O44IV;Remikiren;Ro-42-5892;CHEMBL31601;(αS)-α-[[(S)-2-(tert-Butylsulfonylmethyl)-1-oxo-3-phenylpropyl]amino]-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-1H-imidazole-4-propanamide;1H-Imidazole-5-propanamide, N-[(1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-α-[[(2S)-2-[[(1,1-dimethylethyl)sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-, (αS)-
- CBNumber
- CB61179651
- Molecular Formula
- C33H50N4O6S
- Formula Weight
- 630.846
- MOL File
- 126222-34-2.mol
N-Bromosuccinimide Price
- Product number
- R143552
- Product name
- Remikiren-d4
- Packaging
- 5mg
- Price
- $13750
- Updated
- 2021/12/16
- Product number
- API0007326
- Product name
- REMIKIREN
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $501.97
- Updated
- 2021/12/16
- Product number
- 61568
- Product name
- Remikiren
- Packaging
- 10mg
- Price
- $13500
- Updated
- 2021/12/16
Remikiren Chemical Properties,Usage,Production
Uses
Remikiren, is a renin inhibitor under development for the treatment of hypertension (high blood pressure).
Definition
ChEBI: Remikiren is an L-histidine derivative that is L-histidine in which one of the amino hydrogens is replaced by a (2S)-2-[(2-methylpropane-2-sulfonyl)methyl]-3-phenylpropanoyl group and the carboxy group is replaced by a [(2S,3R,4S)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino group. It is a renin inhibitor which was under development for the treatment of hypertension (now discontinued). It has a role as an antihypertensive agent, a vasodilator agent, a peptidomimetic and an EC 3.4.23.15 (renin) inhibitor. It is a sulfone, a diol, a secondary carboxamide, a member of cyclopropanes and a L-histidine derivative.
in vivo
Remikiren (0.1, 0.3, 1, 3, 10 mg/kg; p.o.; single) reduces mean arterial blood pressure in a dose-dependent manner in sodium-depleted marmosets and squirrel monkeys[1].
Remikiren (3 mg/kg; p.o.; single) shows the duration of blood pressure decrease more than 24 h in sodium-depleted marmosets[1].
| Animal Model: | Marmosets and squirrel monkeys (sodium-depleted)[1]. |
| Dosage: | 0.1, 0.3, 1, 3, 10 mg/kg |
| Administration: | Oral administration; single. |
| Result: | Decreased mean arterial pressure (MAP) by 20-25 mm Hg when at 0.1 mg/kg. Reached the maximal decrease (30 mm Hg) of MAP with 1 mg/kg in marmosets. Decreasesd 35 mm Hg blood pressure with 3-10 mg/kg in squirrel monkeys. |
| Animal Model: | Marmosets (sodium-depleted)[1]. |
| Dosage: | 3 mg/kg |
| Administration: | Oral administration; single. |
| Result: | Showed MAP fell by 30 mm Hg, which lasting more than 24 h. |